Whalesbook
Dr. Reddy's Secures Approval for Oral Semaglutide
Dr. Reddy's Laboratories has secured final approval from India's Central Drug Standard Control Organisation (CDSCO) for its generic oral semaglutide tablets. This marks a significant entry into the rapidly expanding ₹1,600-crore market for weight-loss and anti-diabetes treatments. The regulatory clearance comes amid complex market dynamics, including patent disputes, aggressive pricing from competitors, and recent regulatory challenges in other regions.
Market Entry, Clinical Data, and Competition
The approval covers generic oral semaglutide tablets in 3 mg, 7 mg, and 14 mg strengths. Clinically, the drug demonstrated non-inferiority to Novo Nordisk's Rybelsus in head-to-head studies and is intended as a supplementary treatment for type-2 diabetes mellitus. As of April 15, 2026, Dr. Reddy's stock closed around ₹1,235.00 with 1.46 million shares traded, reflecting a market capitalization of ₹1.03 lakh crore and a P/E ratio of 18.5. Market sentiment may be cautious due to ongoing legal challenges and expected price declines.
India's GLP-1 receptor agonist market is rapidly changing after Novo Nordisk's core semaglutide patent expired in March 2026. This has led over a dozen domestic companies, including Sun Pharma, Zydus Lifesciences, Torrent Pharma, Lupin, and Natco, to launch or prepare their own versions. Torrent Pharma has already established an interim agreement related to SNAC concentration in its products, Semalix and Sembolic, using 0.53 mmol, which is below Novo Nordisk's claimed range. Dr. Reddy's is targeting about 7% of the market, aiming to follow Torrent's 8%.
Novo Nordisk retains an oral formulation patent lasting until 2031. This patent makes the SNAC concentration a crucial point in its ongoing litigation against Dr. Reddy's and Torrent Pharma. The weight-loss drug sector has seen substantial growth, with Rybelsus holding a large share. However, the wave of generics is predicted to cut prices by 50-85% compared to branded versions, intensifying competition and potentially squeezing profit margins for all players.
Legal Challenges and Regulatory Setbacks
Dr. Reddy's faces significant challenges as Novo Nordisk vigorously defends its oral formulation patent, valid until 2031. Novo Nordisk is suing Indian drugmakers, focusing on alleged infringement related to SNAC concentration. Novo Nordisk claims its specific SNAC formulation falls within a 0.65-2.1 mmol range, a detail central to the legal disputes. This uncertainty could restrict Dr. Reddy's market access or result in costly legal settlements.
Adding to these concerns, Dr. Reddy's recently experienced a regulatory setback in Brazil. ANVISA denied registration for its semaglutide generic, Embeltah, citing issues with efficacy, safety, and quality. This rejection impacts its potential entry into a key emerging market.
The market is also bracing for intense competition, with over 40 generic companies entering. This is expected to cause a sharp price war, potentially impacting profitability. Analyst firm Citi maintains a 'Sell' rating with a target price of ₹1,070, citing these regulatory setbacks and valuation concerns.
Analyst Views and Market Trajectory
Despite the hurdles, some analysts see a positive outlook. HSBC has upgraded Dr. Reddy's to 'Buy' with a target price of ₹1,445, citing strong long-term potential for semaglutide and improved earnings estimates for fiscal years 2027-2028. They view the company's core business and biosimilar platform as steady contributors, with semaglutide expected to significantly boost earnings. Conversely, Citi remains cautious, highlighting risks from escalating competition and execution difficulties in a market that is quickly becoming commoditized. The future market path hinges on the resolution of the SNAC patent disputes and Dr. Reddy's ability to implement its market entry strategy effectively amidst fierce competition and pricing pressures.